22:12 , Dec 14, 2018 |  BioCentury  |  Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation In vitro , cell culture and mouse studies identified an OGG1 inhibitor that could help treat pulmonary inflammation. Screening of a small molecule library via an in vitro activity assay, followed by optimization...
22:57 , Nov 30, 2018 |  BioCentury  |  Finance

Global Dimensions

6 Dimensions Capital has invested in at least nine U.S. biotechs this year out of its inaugural U.S. dollar fund, and the pace is expected to continue. Those investments have caught the eye of the...
21:46 , Nov 9, 2018 |  BioCentury  |  Finance

Doubling down on debt

Increased demand for debt financings led Perceptive Advisors to double the capital for its second debt fund: Perceptive Credit Opportunities Fund II. Perceptive closed Fund II at $675 million, just two years after closing its...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
22:46 , Oct 19, 2018 |  BioCentury  |  Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
23:05 , Oct 5, 2018 |  BioCentury  |  Finance

Risk-sharing at scale

By operating under the Blackstone umbrella, Clarus Ventures will be able to significantly scale up its risk-sharing investment strategy. On Oct. 4, private equity firm Blackstone announced plans to acquire Clarus for undisclosed terms. Clarus...
20:17 , Oct 5, 2018 |  BC Week In Review  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
20:14 , Oct 4, 2018 |  BC Extra  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A heterocycloalkynylbenzimide-based dual DDR1/DDR2 inhibitor could be used to probe the role of two proteins in inflammatory diseases. Chemical synthesis and in vitro activity assays of heterocycloalkynylbenzimide analogs identified a compound that...